Stockholm - Delayed Quote SEK
Biosergen AB (BIOSGN.ST)
At close: November 6 at 5:29 PM GMT+1
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Cost of Revenue
226.0000
456.0000
280.0000
178.0000
--
Gross Profit
-226.0000
-456.0000
-280.0000
-178.0000
--
Operating Expense
26,868.0000
27,179.0000
34,524.0000
33,900.0000
6,226.0000
Operating Income
-27,094.0000
-27,635.0000
-34,804.0000
-34,078.0000
-6,226.0000
Net Non Operating Interest Income Expense
124.0000
228.0000
81.0000
-240.0000
--
Pretax Income
-26,600.0000
-27,037.0000
-34,048.0000
-34,318.0000
-6,724.0000
Net Income Common Stockholders
-26,600.0000
-27,037.0000
-34,048.0000
-34,318.0000
-6,724.0000
Diluted NI Available to Com Stockholders
-26,600.0000
-27,037.0000
-34,048.0000
-34,318.0000
-6,724.0000
Basic EPS
-0.18
-0.31
-0.64
-0.72
-0.15
Diluted EPS
-0.18
-0.31
-0.64
-0.72
-0.15
Basic Average Shares
142,387.1910
86,281.5980
52,832.4390
47,577.0690
43,972.6440
Diluted Average Shares
142,387.1910
86,281.5980
52,832.4390
47,577.0690
43,972.6440
Total Operating Income as Reported
-26,724.0000
-27,265.0000
-34,129.0000
-34,078.0000
-6,226.0000
Total Expenses
27,094.0000
27,635.0000
34,804.0000
34,078.0000
6,226.0000
Net Income from Continuing & Discontinued Operation
-26,600.0000
-27,037.0000
-34,048.0000
-34,318.0000
-6,724.0000
Normalized Income
-26,600.0000
-27,037.0000
-34,048.0000
-34,318.0000
-6,724.0000
Interest Income
--
237.0000
135.0000
--
--
Interest Expense
--
9.0000
54.0000
240.0000
--
Net Interest Income
124.0000
228.0000
81.0000
-240.0000
--
EBIT
-26,487.0000
-27,028.0000
-33,994.0000
-34,078.0000
-6,226.0000
EBITDA
-26,487.0000
-27,028.0000
-33,994.0000
-34,078.0000
-6,226.0000
Reconciled Cost of Revenue
226.0000
456.0000
280.0000
178.0000
--
Net Income from Continuing Operation Net Minority Interest
-26,600.0000
-27,037.0000
-34,048.0000
-34,318.0000
-6,724.0000
Normalized EBITDA
-26,487.0000
-27,028.0000
-33,994.0000
-34,078.0000
-6,226.0000
12/31/2020 - 6/24/2021
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
DIABIO.ST Diagonal Bio AB (publ)
0.0319
-4.20%
ATORX.ST Alligator Bioscience AB (publ)
0.6620
-8.06%
PILA.ST Pila Pharma AB (publ)
4.6700
-2.71%
LIDDS.ST LIDDS AB (publ)
0.1010
-36.87%
CHOSA.ST CHOSA Oncology AB
0.7000
-1.41%
APTA.ST Aptahem AB (publ)
1.6000
-3.03%
0H22.IL BioInvent International AB (publ)
45.10
+0.84%
ZICC.ST Ziccum AB (publ)
2.3500
-0.84%
NANECH.ST NanoEcho AB
0.2300
+0.88%
PCIB.OL PCI Biotech Holding ASA
1.6500
+0.86%